PLEASANTON, Calif., March 17, 2017 /PRNewswire/ -- Roche (SIX:
RO, ROG; OTCQX: RHHBY) announced today that it has launched a new instrument for nucleic acid extraction and purification, the
MagNA Pure 24 System. The new system offers an extraction solution with on-board primary sample handling for low to medium
throughput customers who require high quality nucleic acid extractions.
Nucleic acid extraction is the first step in molecular testing and is critical to lab efficiency. The MagNA Pure 24 System is
a fully automated clinical sample extractor that delivers walk-away automation, while minimizing hands-on time and purification
variability. The MagNA Pure 24 System is capable of extracting nucleic acids from a wide range of human sample types with a
single universal reagent kit, offering customers the flexibility and standardization they need for their downstream
workflow.
"The MagNA Pure 24 System builds on the legacy of the MagNA Pure family of products and is designed to meet current and future
needs of molecular testing laboratories," said Uwe Oberlaender, Head of Roche Molecular
Diagnostics. "To those who value the importance of starting their genomic workflow with highly purified nucleic acids, this new
system will offer significant benefits."
The MagNA Pure 24 System is IVD/CE-IVD labelled and is now available in most countries, including the U.S. and countries
accepting CE mark.
About MagNA Pure Systems
For more than 20 years, the Roche MagNA Pure System nucleic acid extraction and purification systems have been ensuring purity,
reproducibility, and laboratory efficiency obtained only by automated magnetic bead-based technology. Using the MagNA Pure
Systems, laboratories can extract a wide range of starting materials and can continue downstream genomic workflow with
high-quality nucleic acids.
The MagNA Pure Systems empower scientists and laboratories to achieve meaningful results with confidence with simplified
sample preparation for dramatic reduction of handling errors, preloaded protocols, and intuitive software.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined
strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy
that aims to fit the right treatment to each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious
diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and
tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable
contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant
stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential
Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader
in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones
Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in
2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D
and posted sales of CHF 50.6 billion. Genentech, in the United
States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical,
Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For media inquiries please contact:
Todd Siesky, Roche Molecular Systems, Inc.
888-545-2443
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-magna-pure-24-system-by-roche-offers-labs-improved-flexibility-and-automation-300425040.html
SOURCE Roche